Alembic Pharmaceuticals Intrinsic Value
Alembic Pharmaceuticals (APLLTD) median intrinsic value is ₹1061.05 from 9 valuation models (range ₹241–₹1888), vs current price ₹755.00 — +40.5% upside (Trading Below Calculated Value), margin of safety 28.8%. For current market price and key ratios, visit APLLTD company profile.
APLLTD Valuation Methods Summary — DCF, Graham Number & P/E
Alembic Pharmaceuticals intrinsic value across 9 models vs current price ₹755.00 — upside/downside and value range per method. Also explore APLLTD share price history to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹827.20 | ₹661.76 - ₹992.64 | +9.6% | EPS: ₹37.60, Sector P/E: 22x |
| Book Value Method | asset | ₹1887.50 | ₹1698.75 - ₹2076.25 | +150.0% | Book Value/Share: ₹1330.77, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1510.00 | ₹1359.00 - ₹1661.00 | +100.0% | Revenue/Share: ₹1968.21, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1510.00 | ₹1359.00 - ₹1661.00 | +100.0% | EBITDA: ₹1296.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹302.00 | ₹241.60 - ₹362.40 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹240.64 | ₹216.58 - ₹264.70 | -68.1% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹580.92 | ₹522.83 - ₹639.01 | -23.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1510.00 | ₹1359.00 - ₹1661.00 | +100.0% | ROE: 14.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1061.05 | ₹954.94 - ₹1167.15 | +40.5% | EPS: ₹37.60, BVPS: ₹1330.77 |
APLLTD Intrinsic Value vs Market Price — All Valuation Models
Alembic Pharmaceuticals fair value range ₹241–₹1888 vs current market price ₹755.00 across 9 valuation models. Read APLLTD ex-dividend dates for the complete payout history and dividend yield track record.
APLLTD Intrinsic Value Analysis — Undervalued or Overvalued?
Alembic Pharmaceuticals median intrinsic value ₹1061.05, current price ₹755.00 — Trading Below Calculated Value by 40.5%, margin of safety 28.8%.
What is the intrinsic value of APLLTD?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Alembic Pharmaceuticals (APLLTD) is ₹1061.05 (median value). With the current market price of ₹755.00, this represents a +40.5% variance from our estimated fair value.
The valuation range spans from ₹240.64 to ₹1887.50, indicating ₹240.64 - ₹1887.50.
Is APLLTD undervalued or overvalued?
Based on our multi-method analysis, Alembic Pharmaceuticals (APLLTD) appears to be trading below calculated value by approximately 40.5%.
APLLTD Financial Health — Key Ratios vs Industry Benchmarks
Alembic Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 23.91 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.99x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
APLLTD Cash Flow Quality — Operating & Free Cash Flow
Alembic Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹88 Cr | ₹-196 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹803 Cr | ₹643 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹724 Cr | ₹500 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹552 Cr | ₹366 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,463 Cr | ₹1,043 Cr | Positive Free Cash Flow | 8/10 |